Turski Christopher A, Georgiou Michalis, Puente Cesar Estrada, Sarici Kubra, Zhou Xiao, Maldonado Ramiro S
Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
J Ophthalmol. 2025 Aug 28;2025:5231278. doi: 10.1155/joph/5231278. eCollection 2025.
To investigate whether supplementation with dietary antioxidants has an effect on the yearly progression rate of atrophic lesions in autosomal recessive Stargardt disease (STGD1), as derived from fundus autofluorescence (FAF). Retrospective study of patients with molecularly confirmed STGD1 aged ≥ 6 years at baseline and presence of an atrophic lesion of ≥ 250 μm in diameter, who underwent FAF imaging between 01/01/2010 and 10/31/2023. Patients were grouped into supplement takers and nontakers based on the daily intake of lutein, zeaxanthin, saffron, and N-acetylcysteine. Baseline and follow-up FAF images were graded by two readers. Variables assessed included total area of decreased FAF (DAF) and effective lesion size of total DAF, calculated as a square root transformation. Annual atrophy growth rates were calculated for both subgroups and compared. A total of 53 eyes of 53 patients were enrolled. Thirty-three patients were categorized as supplement takers (mean age 34 ± 20.3 years, 57.6% female) and 20 patients as nontakers (mean age 29.5 ± 16.6 years, 65% female). Mean growth rates of DAF were 0.61 ± 0.72 mm/year for supplement takers and 0.49 ± 0.55 mm/year for nontakers (=0.9). The mean observation period was 2 years (range 0.5-5.6) and 4.5 years (range 1-10.3), for supplement takers and for nontakers, respectively. Supplementation with dietary antioxidants did not result in a slower progression rate of DAF lesions in STGD1. Further investigation with randomized trials is needed for evidence-based use of antioxidant supplements for the disease.
为了研究补充膳食抗氧化剂是否对常染色体隐性遗传性斯塔加特病（STGD1）萎缩性病变的年进展率有影响，该进展率由眼底自发荧光（FAF）得出。对基线年龄≥6岁且存在直径≥250μm萎缩性病变、在2010年1月1日至2023年10月31日期间接受FAF成像的分子确诊STGD1患者进行回顾性研究。根据叶黄素、玉米黄质、藏红花和N - 乙酰半胱氨酸的每日摄入量，将患者分为补充剂服用者和非服用者。基线和随访的FAF图像由两名阅片者进行分级。评估的变量包括FAF降低区域（DAF）的总面积以及总DAF的有效病变大小，通过平方根变换计算得出。计算两个亚组的年萎缩增长率并进行比较。共纳入53例患者的53只眼。33例患者被归类为补充剂服用者（平均年龄34±20.3岁，57.6%为女性），20例患者为非服用者（平均年龄29.5±16.6岁，65%为女性）。补充剂服用者DAF的平均增长率为0.61±0.72mm/年，非服用者为0.49±0.55mm/年（P = 0.9）。补充剂服用者和非服用者的平均观察期分别为2年（范围0.5 - 5.6）和4.5年（范围1 - 10.3）。补充膳食抗氧化剂并未导致STGD1中DAF病变的进展速度减慢。需要通过随机试验进行进一步研究，以便为该疾病基于证据使用抗氧化剂补充剂提供依据。
